| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-12-13 |
| タイトル |
|
|
タイトル |
Clinical efficacy and tolerability of zonisamide monotherapy in dogs with newly diagnosed idiopathic epilepsy: Prospective open‐label uncontrolled multicenter trial |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Saito, Miyoko
Nomura, Akinori
Hasegawa, Daisuke
Watanabe, Naoyuki
Uchida, Keiko
Okuno, Seiichi
Nakai, Masahiro
Orito, Kensuke
|
| Abstract |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Zonisamide (ZNS) is a newer generation antiseizure medication (ASM) used to treat epilepsy in dogs and cats. However, scientific and clinical information, particularly regarding monotherapy, is limited.
Objectives: To evaluate the antiseizure efficacy and tolerability of ZNS monotherapy in dogs with newly diagnosed idiopathic epilepsy (IE).
Animals: Study included 56 client-owned dogs newly diagnosed with IE.
Methods: This was a prospective multicenter, open-label, uncontrolled study. All dogs were ASM-naïve and had ≥2 seizures within 12 weeks. Dogs were administered 2.7-14.4 mg/kg ZNS PO q12h and followed up for ≥12 weeks. Data from the 12-week maintenance treatment period were compared with those from the 4- to 12-week pretreatment period for efficacy evaluation. Data from the entire ZNS administration period were used to assess tolerability.
Results: Fifty-six dogs were included in our study. Of the dogs, 53 were assessed for efficacy; 40 (76%) had a ≥ 50% reduction in seizure frequency, and 29 (55%) achieved seizure freedom. For 90% of the dogs with ≥50% reduction in seizure frequency, the mean ZNS dose was 4.8 (range, 2.7-8.6) mg/kg q12h and the mean trough plasma ZNS concentration was 18.9 (range, 8.0-48.0) μg/mL. In 7 of the 56 dogs (13%), reduced activity, decreased appetite, vomiting, hindlimb weakness, soft stools, or constipation was observed, albeit mild and temporary. Laboratory tests revealed no relevant changes.
Conclusions and Clinical Importance: Our study suggests that ZNS monotherapy is effective and well-tolerated in dogs with newly diagnosed IE. |
|
言語 |
en |
| 書誌情報 |
Journal of Veterinary Internal Medicine
巻 38,
p. 2228-2236,
発行日 2024-05-23
|
| 出版者 |
|
|
出版者 |
Wiley |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/jvim.17108 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 査読 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
査読あり |
Veterinary Internal Medicne - 2024 - Saito - Clinical efficacy and tolerability of zonisamide monotherapy in dogs with.pdf (728 KB)
